References of "REGINSTER, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailCost-effectiveness of Denosumab compared with generic alendronate in the treatment of postmenopausal osteoporotic women
Hiligsmann, Mickaël ULg; Reginster, Jean-Yves ULg

in Osteoporosis International (2011, March), 22(Suppl.1), 112-113

Detailed reference viewed: 44 (11 ULg)
Full Text
Peer Reviewed
See detailLong-term efficacy and safety of strontium ranelate in postmenopausal osteoporotic women: results over 10 years
Reginster, Jean-Yves ULg; Kaufman, Jean-Marc; Devogelaer, Jean-Pierre et al

in Osteoporosis International (2011, March), 22(Suppl.1), 110-111

Detailed reference viewed: 38 (6 ULg)
Full Text
Peer Reviewed
See detailHospitalisation costs of hip fractures in Belgium
Hiligsmann, Mickaël ULg; Gathon, Henry-Jean ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2011, March), 22(Suppl.1), 332

Detailed reference viewed: 33 (7 ULg)
Full Text
Peer Reviewed
See detailPatient out-of-pocket contributions related to hip fracture hospital costs in Belgium
Hiligsmann, Mickaël ULg; Gathon, Henry-Jean ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2011, March), 22(Suppl.1), 333

Detailed reference viewed: 46 (23 ULg)
Full Text
Peer Reviewed
See detailProtecting men and women from fracture
Reginster, Jean-Yves ULg

in Osteoporosis International (2011, March), 22(Suppl.1), 413-414

Detailed reference viewed: 26 (5 ULg)
Full Text
Peer Reviewed
See detailThe true clinical relevance of crystalline glucosamine sulphate in the treatment of knee osteoarthritis
Reginster, Jean-Yves ULg

in Osteoporosis International (2011, March), 22(Suppl.1), 410

Detailed reference viewed: 105 (4 ULg)
Full Text
Peer Reviewed
See detailAntifracture efficacy and safety of once-yearly Zoledronic acid 5mg in men with osteoporosis: a prospective, randomized, controlled trial
Boonen, Steven; Su, Guoqin; Incera, Elodie et al

in Osteoporosis International (2011, March), 22(Suppl.1), 112

Detailed reference viewed: 58 (1 ULg)
Full Text
Peer Reviewed
See detailFive-year Denosumab treatment of postmenopausal women with osteoporosis: results from the first two years of the freedom trial extension
Papapoulos, S.; Man, Z.; Mellstrom, D. et al

in Osteoporosis International (2011, March), 22(Suppl.1), 107-108

Detailed reference viewed: 98 (6 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate increases cell viability in IL-1 beta stimulated human chondrocytes
Merville, Marie-Paule ULg; Deroyer, Céline ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2011, March), 22(Suppl.1), 53-54384

Detailed reference viewed: 41 (22 ULg)
Full Text
Peer Reviewed
See detailRisk of hip fracture in community-dwelling and institutionalized osteoporotic patients: a 3-year study
Bruyère, Olivier ULg; Hiligsmann, Mickaël ULg; Zegels, Brigitte ULg et al

in Osteoporosis International (2011, March), 22(Suppl.1), 332-333

Detailed reference viewed: 22 (7 ULg)
Full Text
Peer Reviewed
See detailIncidence of hip fracture in Belgium between 2000 and 2007 and future projections
Hiligsmann, Mickaël ULg; Bruyère, Olivier ULg; Detilleux, Johann ULg et al

in Osteoporosis International (2011, March), 22(Suppl.1), 145

Detailed reference viewed: 19 (6 ULg)
Full Text
Peer Reviewed
See detailRelationship between changes in bone mineral density or bone turnover markers and vertebral fracture incidence in patients treated with Bazedoxifene
Bruyère, Olivier ULg; Detilleux, Johann ULg; Chines, Arkadi et al

in Osteoporosis International (2011, March), 22(Suppl.1), 324

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailStable precision over time when assessing the cartilage loss on knee osteoarthritis radiograph
DEROISY, Rita ULg; Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Osteoporosis International (2011, March), 22(Suppl.1), 42-43246

Detailed reference viewed: 16 (5 ULg)
Full Text
Peer Reviewed
See detailArzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.
Cummings, S. R.; McClung, M.; Reginster, Jean-Yves ULg et al

in Journal of Bone and Mineral Research (2011), 26(2), 397-404

BACKGROUND: Arzoxifene is a selective estrogen receptor modulator (SERM) more potent in preclinical testing than currently available agents. Its effects on clinical outcomes are not known. METHODS: In a ... [more ▼]

BACKGROUND: Arzoxifene is a selective estrogen receptor modulator (SERM) more potent in preclinical testing than currently available agents. Its effects on clinical outcomes are not known. METHODS: In a randomized blinded trial, women age 60 to 85 years with osteoporosis, defined as a femoral neck or lumbar spine bone mineral density T-score less than or equal to -2.5 or a vertebral fracture, and women with low bone mass, defined as a bone density T-score less than or equal to -1.0 and above -2.5, were assigned to arzoxifene 20 mg or placebo daily. The primary endpoints were new vertebral fracture in those with osteoporosis, and invasive breast cancer in the overall population. RESULTS: After 3 years, the cumulative incidence of vertebral fractures in patients with osteoporosis was 2.3% lower in the arzoxifene than in the placebo group, a 41% relative risk reduction (95% CI 0.45 to 0.77; P<0.001). In the overall population, the cumulative incidence of invasive breast cancer over 4 years was reduced by 1.3%, with a 56% relative reduction in risk (HR=0.44; 95% CI 0.26 to 0.76; P<0.001); there was no significant decrease in nonvertebral fracture risk. Arzoxifene increased the cumulative incidence of venous thromboembolic events by 0.7%, with a 2.3-fold relative increase (95% CI 1.5 to 3.7). CONCLUSION: Like other SERMs, arzoxifene decreased vertebral fractures and invasive breast cancer while the risk of venous thromboembolic events increased. (c) 2010 American Society for Bone and Mineral Research. [less ▲]

Detailed reference viewed: 14 (2 ULg)